Recruiting

Mindfulness and Wearable Biosensors to Prevent Hypertensive Disorders of Pregnancy

The MINDBP study will enroll 90 pregnant women at risk for HDP across two sites (MCW and Brown) and randomize them to: (1) mindfulness training (MT) plus wearable biosensors, (2) MT alone, or (3) routine prenatal care. MT participants will receive 8 weekly phone-based MT sessions plus two booster sessions at 1 and 2 months post-intervention. The primary outcome is study feasibility.

ClinicalTrials.gov IDNCT07218237
PhaseNA
Enrollment90
SponsorMedical College of Wisconsin
Age18 Years
SexFEMALE
I'm interested View official listing

Conditions studied

Preeclampsia

About this study

The MINDBP study will enroll 90 pregnant women at risk for HDP across two sites (MCW and Brown) and randomize them to: (1) mindfulness training (MT) plus wearable biosensors, (2) MT alone, or (3) routine prenatal care. MT participants will receive 8 weekly phone-based MT sessions plus two booster sessions at 1 and 2 months post-intervention. The primary outcome is study feasibility.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Pregnant patients at gestational age \<= 16 weeks * Live, non-anomalous gestation * Normotensive at enrollment * Meet criteria consistent with 'moderate' to 'high' risk for preeclampsia based on ACOG/USPSTF guidelines for low-dose aspirin administration to prevent hypertensive disorders of pregnancy Exclusion Criteria: * Multiple gestation * Chronic (pregestational hypertension) * Inability of unwillingness to provide informed consent * Active suicidality or psychosis * Ongoing mind-body practice (e.g., yoga, meditation, mindfulness \>= once per week)

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.